DOSSIER · 13F-HR · Q3 2026

Sanofi

$630M in tracked AUM across 16 positions as of Q3 2026.

S
CIK 0001121404 · last filed Sep 30, 2026
Total AUM
$630M
as of Q3 2026
Holdings
16
—
positions
Whale Score
78
78
strong
Activity
—
no data
changes this Q
AI Analysis · Q3 2026

Portfolio Overview

The filing for Sanofi (CIK: 0001121404) as of September 30, 2025, reveals a highly concentrated, specialized investment portfolio totaling $156.10 million. This represents a decrease of 11.2% from the previous quarter's value of $175.74 million. The portfolio is extremely narrow in scope, containing only five holdings. This lack of diversification suggests that the portfolio is not managed for general market exposure or broad risk mitigation, but rather for specific strat...

Key Holdings

The portfolio is dominated by a single high-conviction position: MeiraGTx Holdings plc, which accounts for $100.39 million or 64.31% of the total assets. With 12.20 million shares, this position dictates the performance of the entire portfolio. The second-largest holding is Inhibrx Biosciences, Inc., comprising 24.98% of the portfolio ($39.00 million). Together, these two positions represent nearly 90% of the fund's total value, indicating a "barbell" strategy where the firm relies heavily on the success of two primary assets.

Analysis generated by 13F Insight from SEC Form 13F filing data · Q3 2026. Methodology

Quarter at a glance — Q3 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q3 2026. Source: SEC EDGAR 13F-HR filings.

#HoldingValueSharesWeight
01
G59665102
MeiraGTx Holdings plc
$134M12.2M21.3%
02
INBX
Inhibrx Biosciences, Inc.
$116M1.2M18.4%
03
NVAX
Novavax
$74M6.9M11.8%
04
KRSA
Korsana Biosciences
$64M2.0M10.1%
05
ODTX
Odyssey Therapeutics Inc.
$44M2.0M7.0%
06
ANAB
AnaptysBio
$41M822K6.6%
07
AGMB
Agomab Therapeutics NV
$31M2.8M4.9%
08
TRAX
First Tracks Biotherapeutics Inc.
$29M822K4.6%
09
ETRA
Electra Therapeutics Inc
$28M2.5M4.4%
10
ATTO
Attovia Therapeutics Inc
$19M1.1M2.9%

Filing history

2026Q3Sep 30
$630M▲ 17.9%
16 positionsView →
2026Q2Jun 30
$534M▲ 59.0%
10 positionsView →
2026Q1Mar 31
$336M▲ 8.2%
9 positionsView →
2025Q4Dec 31
$310M▲ 98.9%
8 positionsView →
2025Q3Sep 30
$156M▼ 11.2%
5 positionsLocked
2025Q2Jun 30
$176M▲ 68.2%
10 positionsLocked
2025Q1Mar 31
$105M▼ 40.1%
5 positionsLocked
2024Q4Dec 31
$174M—
9 positionsLocked